@prefix biolink: .
@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association a rdf:Statement;
rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
rdfs:label "ABSTRALĀ® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving, and who are tolerant to, around-the-clock opioid therapy for their underlying persistent cancer pain.";
biolink:association_type biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
biolink:has_population_context sub:cohort;
biolink:provided_by ;
biolink:publications ;
biolink:relation schema:TreatmentIndication .
sub:cohort rdfs:label "in cancer patients 18 years of age and older";
schema:requiredMinAge "18";
biolink:category biolink:Cohort;
biolink:has_phenotype .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "GFGdoa+Dvg/NF7sXwCdUcm6zr8PznjOXsWnIcOEvPYMO+uKt1ClF4U4POL73DDf9/DZ/DIi1ZpqvCZVEOYbT71sfsFzP6lGfFvGgGZZElHIRz+hm4ONxwmKPkBcNrMgGLaA1kOVslvKUa+gqBQr43Q4GMCwyL4ZQFJr6hcQMW34=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-04-12T09:15:24.446+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}